Serbian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
neuroendocrine tumors/умор
Веза се чува у привремену меморију
Страна 1 од 93 резултати
Calcitonin-secreting pancreatic neuroendocrine tumors: a case report and review of the literature.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
OBJECTIVE
We report the presentation and novel therapy of a calcitonin-secreting pancreatic neuroendocrine tumor (PNET) and review the literature on this unusual neoplasm.
METHODS
We cite the history of a 38-year-old male who presented with fatigue, weight loss, and diarrhea and was found to have a
Metastatic small bowel neuroendocrine tumour with bilateral carcinoid heart disease.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
A 63-year-old woman was admitted with a year's history of exertional breathlessness, anxiety attacks, syncopal episodes, diarrhoea, fatigue, reduced appetite, 2 stones weight loss, and flushing affecting her face and trunk. Investigations revealed raised urine 5-hydroxy indole acetic acid (5-HIAA)
Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Non-islet cell tumour hypoglycaemia in a patient with a well-differentiated gastric neuroendocrine tumour.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
A 61-year-old man, without noteworthy medical history, presented with complaints of progressive fatigue and flushes. Diagnostic imaging revealed a large tumour in the stomach with liver metastases, and histopathological examination showed a well-differentiated gastric neuroendocrine tumour (NET).
Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND
Neuroendocrine tumours (NETs) are rare, and when metastatic NETs are incurable, the tumours are frequently slowly growing. Patients may be confronted with disease-specific problems and distinct issues when accessing health-care. We aimed to assess perceptions of care coordination,
Practical guide to supportive care of patients with functional neuroendocrine tumors.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Supportive care of patients with functional neuroendocrine tumors (NETs) has evolved to include the use of multiple targeted agents to control paraneoplastic states and newer surgical and interventional radiologic techniques to reduce tumor bulk. Challenges encountered by the clinician are the
Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND
The objective of this paper was to assess the safety and efficacy of sunitinib malate in patients with well-differentiated metastatic pancreatic neuroendocrine neoplasms (PNENs) who relapsed on standard therapy.
METHODS
Overall, eight patients with well-differentiated pancreatic
Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND
Patients with advanced well-differentiated neuroendocrine tumours (Wd-NETs) are commonly treated with somatostatin analogues (SSAs). Some patients may develop SSA-related side effects such as pancreatic exocrine insufficiency (PEI).
METHODS
In this prospective, observational study, the
Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Objective: To examine patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who receive sequential treatment with somatostatin analogs. Materials and Methods: This retrospective chart review examined lanreotide depot/autogel tolerability and efficacy among
Carboplatin-related acute interstitial nephritis in a patient with pancreatic neuroendocrine tumor.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Carboplatin is characterized by low nephrotoxicity, including acute tubular necrosis (ATN), compared to a conventional platinum complex due to its low accumulative property in the renal tubules. Therefore, there are extremely few reports of carboplatin-induced kidney injury and only one case has
E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
CONCLUSIONS
Rate of progression-free survival at a particular point in time, i.e., a landmark analysis, is a difficult endpoint for a heterogenous malignancy such as neuroendocrine cancer.Landmark analyses can also be complicated by evolution in the standard of care during the conduct of a clinical
Long-term survival of a patient with an inoperable thymic neuroendocrine tumor stage IIIa under sole treatment with Viscum album extract: A CARE compliant clinical case report.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND
This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).
METHODS
Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week
Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Neuroendocrine tumors (NETs) are understudied and have limited systemic treatment options. Prior studies for patients with advanced NETs have demonstrated promising results when antimetabolite agents, including fluoropyrimidines, were combined with temozolomide TMZ. TAS-102 (trifluridine/tipiracil)
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
On May 20, 2011, the U.S. Food and Drug Administration (FDA) approved sunitinib malate capsules (Sutent®; Pfizer, Inc., New York) for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNETs) in patients with unresectable locally advanced or metastatic disease. In a
Најкомплетнија база лековитог биља подржана науком
- Ради на 55 језика
- Биљни лекови потпомогнути науком
- Препознавање биљака по слици
- Интерактивна ГПС мапа - означите биље на локацији (ускоро)
- Читајте научне публикације повезане са вашом претрагом
- Претражите лековито биље по њиховим ефектима
- Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима
Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима
